Synbody Biotechnology Inc. is using synthetic peptides to create flexible, modular ligands that have high affinity and specificity for their targets. The biotech says its ligands - dubbed synbodies - are easy to manufacture and will be useful for hitting targets that would otherwise be difficult to drug with small molecules and antibodies.

Synbody was founded to commercialize a technology invented by Arizona State University researchers for discovering and engineering peptide-based ligands. The company has exclusively licensed five patent families covering the technology from the university.